Hogan Lovells Helps Angelini Buy Catalyst Pharma For $4.1B
Angelini Pharma SpA will buy U.S. rival Catalyst Pharmaceuticals Inc. for $4.1 billion in cash, the companies said Thursday, a transaction that will give the Italian company access to therapeutics for...To view the full article, register now.
Already a subscriber? Click here to view full article